3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
4
Nausea
3
Sezary Syndrome
1
Pruritus
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Brenner Tumor
1
Breast Neoplasms
1
Interventions
Sunitinib
27
Nivolumab
26
pembrolizumab
23
Sorafenib
17
Everolimus
14
Cyclophosphamide
13
Interleukin-2
10
Bevacizumab
10
Radiosurgery
9
spartalizumab
8
pazopanib
7
atezolizumab
7
Ipilimumab
7
Axitinib
7
fludarabine
6
aldesleukin
6
cabozantinib
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gemcitabine
5
peginterferon alfa-2b
4
avelumab
4
Nephrectomy
4
Irinotecan
4
Introns
4
Gene Expression Profiling
4
Capecitabine
4
lenvatinib
3
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Renal Cell
×
Aprepitant
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts